加载中
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
常规交易时段
US$62.38
−US$0.41 · -0.65%
盘中时间采用ET。市场数据可能有所延迟。
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
日内区间
当前US$62.38
52周区间
当前US$62.38
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
47
合理估值
情绪
71
看涨
风险
25
中等风险
动量
66
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
日内区间
当前US$62.38
52周区间
当前US$62.38
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 8803.9万 USD | 1847.4万 USD | 753万 USD | 9458.8万 USD | 7042.8万 USD |
| 销货成本 | 1012.5万 USD | 3.39亿 USD | 3.3亿 USD | 2.41亿 USD | 1.6亿 USD |
| 毛利 | 7791.4万 USD | −3.21亿 USD | −3.23亿 USD | −1.46亿 USD | −8951万 USD |
| 研究与开发 | 4.06亿 USD | 3.39亿 USD | 3.3亿 USD | 2.41亿 USD | 1.6亿 USD |
| 销售、一般及管理费用 | 2.84亿 USD | 2.15亿 USD | 1.74亿 USD | 1.78亿 USD | 9680.3万 USD |
| 营业费用 | 6.9亿 USD | 2.15亿 USD | 1.74亿 USD | 1.78亿 USD | 9680.3万 USD |
| 利息收入 | 4842万 USD | 5153.4万 USD | 2762.9万 USD | 1134.2万 USD | 33.1万 USD |
| 利息支出 | 1.04亿 USD | 8651.2万 USD | 5766.8万 USD | 5115.6万 USD | 2933.2万 USD |
| 折旧和摊销 | 1012.5万 USD | 953.1万 USD | 1189.2万 USD | 581.4万 USD | 227.6万 USD |
| 营业利润 | −6.12亿 USD | −5.36亿 USD | −4.96亿 USD | −3.24亿 USD | −1.86亿 USD |
| 净利润 | −7.85亿 USD | −5.9亿 USD | −5.26亿 USD | −3.89亿 USD | −2.15亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$114.56
上涨空间 83.65%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2013年6月25日 | 1:6 | — | — |
已生效 2013年6月25日
1:6
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3.07亿0.01%2.3万亿 USD0.03%US$380.91-0.17%
Vanguard Morningstar Small-Cap ETFVB2.22亿0.12%1853亿 USD0.03%US$287.02-0.40%
iShares Russell 2000 ETFIWM2.17亿0.28%787.4亿 USD0.19%US$276.36-0.55%
Vanguard Morningstar Small-Cap Growth ETFVBK1.27亿0.28%447亿 USD0.05%US$337.85-0.89%
State Street SPDR S&P Biotech ETFXBI1.23亿1.25%103.03亿 USD0.35%US$148.33-2.03%
Vanguard Extended Market ETFVXF1.12亿0.11%954亿 USD0.05%US$232.02-0.64%
T. Rowe Capital Appreciation Equity ETFTCAF8267.56万0.91%91.19亿 USD0.31%US$43.485-0.17%
iShares Russell 2000 Value ETFIWN7027.72万0.51%137.49亿 USD0.24%US$210.59-0.24%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap Growth ETFVBKState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFT. Rowe Capital Appreciation Equity ETFTCAFiShares Russell 2000 Value ETFIWNAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
